Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S

Iovance Biotherapeutics IOVA incurred a second-quarter 2025 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 29 cents. In the year-ago quarter, the company reported a loss of 34 cents per share.
Quarterly revenues rose 93% year over year to $60.0 million, entirely from the sales of its two marketed drugs. Yet, this figure also missed the Zacks Consensus Estimate of $66.4 million.
More on IOVA’s Earnings
Iovance currently has two marketed drugs in its portfolio, the IL-2 product Proleukin and the TIL therapy Amtagvi. While Proleukin is approved to treat metastatic renal cell carcinoma and metastatic melanoma in adults, Amtagvi is approved for the advanced melanoma indication.
Iovance recorded $54.1 million from Amtagvi sales during the quarter, compared with $43.6 million in the previous quarter, driven by robust demand for the therapy. This figure marginally beat both the Zacks Consensus Estimate of $53.3 million and our model estimate of $53.5 million. Per IOVA, over 100 patients were infused during the quarter.
Proleukin added $5.9 million during the quarter, down 68% year over year. The metric also missed both the Zacks Consensus Estimate and our model estimate of $18 million, each.
Discussion on IOVA’s Operating Costs
Research & development expenses totaled $79.4 million, up 28% from the year-ago quarter’s level. The uptick was driven primarily by higher employee costs and clinical expenses incurred during the quarter.
Selling, general and administrative expenses declined 5% from the prior-year quarter’s figure to $37.7 million, primarily due to a fall in stock compensation expenses.
IOVA’s Guidance
Iovance reiterated its product revenue guidance for the full year, driven by strong demand for both of its marketed products. It expects this metric to be between $250 million and $300 million.
Alongside the earnings results, Iovance also announced that it is initiating a strategic restructuring plan to save more than $100 million annually in costs starting in 2025. To achieve this target, the company has decided to lay off nearly 19% of its workforce before the end of next month, as well as optimize and refine its cost structure over the next two to three quarters.
Based on the above plan, Iovance expects net cash burn for the next four quarters through the second quarter of 2026 to be less than $245 million. The savings in costs are expected to extend the existing cash runway into the fourth quarter of 2026.
Iovance expects significant growth in total product revenues for 2026 and beyond. It expects gross margins to increase through near-term optimization of manufacturing capacity utilization over the next several years.
Updates on IOVA’s Pipeline & Other News
Regulatory applications for Amtagvi in the melanoma indication are currently under review in the United Kingdom, Canada and Australia, with potential approvals expected throughout this year and early next year. However, the company announced that it had voluntarily withdrawn the regulatory filing for the therapy in the European Union recently due to a lack of alignment with the EMA on clinical data supporting the submission.
Shares of Iovance plummeted nearly 29% in after-market trading yesterday, likely due to this development. Though the company stated that it is currently developing a new strategy for seeking the therapy’s EU approval, it delayed the initial plans of securing a potential approval before this year’s end. This downward trajectory also continued in pre-market today.
Year to date, the stock has plunged 64% compared with the industry’s 1% decline.
Image Source: Zacks Investment Research
Iovance is evaluating Amtagvi, combined with Merck’s PD-L1 inhibitor, Keytruda, in the phase III TILVANCE-301 study as a potential treatment for frontline advanced melanoma. This study will also serve as a confirmatory study seeking full approval for Amtagvi in the melanoma indication.
The company remains on track to share an update from the phase II IOV-LUN-202 study, evaluating Amtagvi in post-anti-PD-1 non-small cell lung cancer (NSCLC), before this year’s end. If results from the study are positive, Iovance expects to secure label expansion for the drug from the FDA in the given indication in 2027. Amtagvi is also being evaluated in separate mid-stage studies for cervical and endometrial cancer indications. Initial results from the endometrial cancer study are expected by this year’s end.
The company also expects to report data from the efficacy portion of the phase II IOV-GM1-201 study, evaluating IOV-4001 in previously treated advanced melanoma, later this year.
IOVA’s Zacks Rank
Iovance currently has a Zacks Rank #4 (Sell).
Iovance Biotherapeutics, Inc. Price
Our Key Picks Among Biotech Stocks
Some other better-ranked stocks from the industry are Genmab GMAB, CorMedix CRMD and Immunocore IMCR. While GMAB sports a Zacks Rank #1 (Strong Buy) at present, CRMD and IMCR each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Genmab’s 2025 EPS have increased from $1.52 to $1.58 over the past 60 days, while the same for 2026 has increased from $1.85 to $1.93. GMAB shares have gained 9% year to date.
Genmab’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 14.90%.
Estimates for CorMedix’s 2025 EPS have increased from 93 cents to 97 cents over the past 60 days, while the same for 2026 has increased from $1.64 to $1.65. CRMD shares have surged 33% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have improved from 86 cents to 68 cents. During the same timeframe, estimates for 2026 loss per share have narrowed from $1.34 to $1.10. IMCR stock has gained 8% so far this year.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
See our %%CTA_TEXT%% report – free today!
7 Best Stocks for the Next 30 Days
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Bio-Techne Corporation TECH is set to release fourth-quarter fiscal 2025 results on Aug. 6, before the opening bell.
The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 56 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 9.8%. The company beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 6.74%.
Q4 Estimates for TECH
The Zacks Consensus Estimate for Bio-Techne’s revenues is pegged at $317.4 million, indicating an increase of 3.7% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS suggests a 2% year-over-year improvement of 50 cents.
Estimate Revision Trend Ahead of TECH’s Q4 Earnings
Estimates for Bio-Techne’s fiscal fourth-quarter earnings have remained constant at 50 cents in the past 60 days.
Let’s briefly review the company’s performance leading up to this announcement.
TECH: Factors at Play
During the May 2025earnings call Bio-Techne management noted that ongoing macro uncertainties around tariffs and potential NIH budget cuts could add to uncertainty for customers and temporarily slow down the growth momentum in the fourth quarter of fiscal 2025. However, the company has been actively working to fully mitigate the cost impact of tariffs by the start of fiscal 2026.
Protein Sciences represents the larger of the two divisions, accounting for 72% of the company’s net sales in the third quarter of fiscal 2025. Revenues in the fiscal fourth quarter may have been modestly impacted by the exclusion of the fetal bovine serum business, which was classified as held-for-sale business and subsequently divested in the second quarter.
Nonetheless, Bio-Techne is expected to have benefited from robust demand for its catalog of research reagents, protein analysis tools and cell therapy workflow solutions. The company’s core portfolio of research-use-only proteomic agents — featuring more than 6,000 proteins and 400,000 antibody types — may have continued to support global customers in advancing therapeutics to enable precision diagnostics. It is also likely to have gained from licensing the biological content to other life science tool companies for use in their assays and consumables.
Bio-Techne Corp Price and EPS Surprise
In addition, the FDA’s recent move to replace animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods may have accelerated growth for Bio-Techne’s organoid solutions. These offer an ethical, cost-effective, and faster alternative for assessing drug efficacy, toxicity and mechanisms of action. Similar to the third quarter, the company is likely to have witnessed strong growth in GMP reagents, from growing reliance on these reagents across all stages of cell therapy development.
In the fiscal fourth quarter, the protein analytical instrumentation business may have continued to demonstrate strong momentum, especially in the Maurice biologics platform. The Maurice family of instruments is expected to have seen strong uptake from the company’s pharma and contract research organization (CRO) partners, alongside gaining traction as a gene therapy QA/QC platform.
Meanwhile, broad-based strength in both instrument placements and consumables pull-through may have supported Biologics' growth in the fiscal fourth quarter. The consensus estimate for the segment’s revenues is pegged at $225 million, up 5.1% from the year-ago reported figure.
Within the Spatial Biology (formerly Diagnostics and Genomics) segment,performance across the OEM diagnostic reagents business and the Asuragen carrier screening and oncology business may have remained stable. Recent innovations at Asuragen, including the AmplideX Nanopore Carrier Screening Plus Kit that leverages its proprietary chemistry to analyze difficult genes, are expected to have supported growth in the fiscal fourth quarter. Additionally, the use and adoption of the ExoDx prostate cancer test is likely to have continued, contributing to growth.
The Spatial Biology segment, which has the highest exposure to U.S. academic end markets, is likely to have faced headwinds from the NIH funding uncertainty. Despite this, the fully automated COMET system is expected to have continued gaining traction. The addition of multiomic capabilities to the COMET installed base may have positioned the system for a steady ramp-up in consumables pull-through of RNA scope reagents, as well as the company’s portfolio of newly validated spatial antibodies. These developments are also likely to have aided growth in the fiscal fourth quarter.
The consensus estimate for Spatial Biology revenues is pegged at $93 million, up 2.2% from the year-ago reported figure.
What Our Model Unveils for TECH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
CorMedix CRMD has an Earnings ESP of +27.12% and a Zacks Rank #1. The company is expected to release second-quarter 2025 results soon.
CRMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.8%. As per the Zacks Consensus Estimate, the company’s second-quarter EPS is expected to surge 180% from the year-ago quarter figure.
Genmab GMAB has an Earnings ESP of +10.03% and a Zacks Rank #1. The company is set to release second-quarter fiscal 2025 results on Aug. 7.
GMAB’s earnings surpassed estimates in two of the trailing four quarters and missed on the other two occasions, with the average surprise being 14.9%. Going by estimates, the company’s second-quarter EPS is expected to rise 77.3% from the year-ago reported figure.
Amneal Pharmaceuticals AMRX has an Earnings ESP of +13.21% and a Zacks Rank #2. The company is slated to release second-quarter 2025 results on Aug. 5.
AMRX’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.3%. The consensus estimate indicates that the company’s second-quarter EPS will increase 12.5% from the year-ago quarter’s figure.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?

Centene Corporation CNC is scheduled to release second-quarter 2025 results on July 25, before the opening bell. The Zacks Consensus Estimate for earnings is pegged at 68 cents per share, which indicates a 71.9% plunge from the prior-year quarter’s number.
The second-quarter earnings estimate has witnessed no upward revisions against two downward movements over the past seven days. Meanwhile, the Zacks Consensus Estimate for revenues is pegged at $43.9 billion, implying 10.3% growth from the year-ago quarter’s figure.
Image Source: Zacks Investment Research
CNC’s Earnings Surprise History
Centene’s bottom line beat estimates in three of the trailing four quarters and missed the mark once, the average surprise being 25.47%. This is depicted in the chart below:
Centene Corporation Price and EPS Surprise
What Our Quantitative Model Unveils for AON
Our proven model does not conclusively predict an earnings beat for Centene this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here, as you see below.
Earnings ESP: Centene has an Earnings ESP of 0.00%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: CNC currently has a Zacks Rank #5 (Strong Sell).
Factors Likely to Shape Centene’s Q2 Results
In the second quarter, revenues of Centene are likely to have benefited on the back of growing premiums resulting from an increased customer base across its Commercial Marketplace business. The business is likely to have received an impetus from new enrolments and strong retention rates. However, the upside is expected to have been partly offset by declining membership in CNC’s Medicaid and Medicare businesses.
The Zacks Consensus Estimate for premiums of Centene is pegged at $39.9 billion, which indicates an improvement of 13.6% from the prior-year quarter’s reported figure. We anticipate premiums at $40.1 billion, up 14% year over year. The consensus mark for membership in the Commercial Marketplace business indicates year-over-year growth of 22.7%.
The Zacks Consensus Estimate for Medicaid and Medicare membership implies year-over-year declines of 1.9% and 9.8%, respectively. Our estimate for overall membership stands at 27.8 million as of June 30, 2025, down 2.5% year over year.
Additionally, lower service revenues are expected to be a partial offset to Centene’s results in the to-be-reported quarter. The consensus mark for service revenues is $774 million, which indicates a 7.1% decline from the year-ago quarter’s reported number. We also expect the same at $774 million.
The health benefits ratio (HBR) of CNC is likely to have witnessed an uptick due to an expanding Marketplace business and increased utilization of specialty drugs in non-low-income PDP members. The Zacks Consensus Estimate for consolidated HBR is 91%, which indicates a deterioration of 300 basis points year over year. Our estimate for HBR is 90.4%.
Centene’s margins are likely to have suffered a setback due to an elevated medical cost level. We expect medical costs to be $36.2 billion for the second quarter, implying an escalation of 17.8% year over year.
Stocks to Consider
Here are some companies from the Medical space, which according to our model, have the right combination of elements to beat on earnings this time around:
Genmab A/S GMAB has an Earnings ESP of +10.03% and a Zacks Rank of 1 at present. The Zacks Consensus Estimate for GMAB’s second-quarter earnings is pegged at 39 cents per share, which implies a 77.3% rise from the year-ago quarter’s figure.
Genmab’s earnings beat estimates in two of the trailing four quarters and missed the mark twice, the average surprise being 14.90%.
Stevanato Group S.p.A. STVN currently has an Earnings ESP of +20.93% and a Zacks Rank of 2. The Zacks Consensus Estimate for STVN’s second-quarter earnings is pegged at 11 cents per share, which implies a 10% rise from the year-ago quarter’s figure.
Stevanato Group’s earnings beat estimates in one of the trailing four quarters and matched the mark thrice, the average surprise being 2.50%.
BioMarin Pharmaceutical Inc. BMRN has an Earnings ESP of +4.39% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for BMRN’s second-quarter earnings is pegged at $1.03 per share, which implies a 7.3% rise from the year-ago quarter’s figure.
BioMarin Pharmaceutical’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.83%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will Escalating Medical Costs Dampen Centene's Q2 Earnings?

Tenet Healthcare Corporation THC reported second-quarter 2025 adjusted earnings per share (EPS) of $4.02, which surpassed the Zacks Consensus Estimate by 41.6%. The bottom line soared 74% year over year.
Net operating revenues advanced 3.2% year over year to $5.3 billion. The top line beat the consensus mark by 2.4%.
The company’s quarterly results were aided by higher same facility revenues, favorable payer mix and improved acuity, which led to strong performance of the Hospital Operations and Services segment. Facility buyouts buoyed the performance of the Ambulatory Care segment. However, the upside was partly offset by rising operating costs—particularly supplies expense.
Tenet Healthcare Corporation Price, Consensus and EPS Surprise
THC’s Q2 Performance
Adjusted net income of $369 million climbed 63.3% year over year in the quarter under review.
Adjusted EBITDA improved 18.6% year over year to $1.1 billion, higher than our estimate of $997 million. The year-over-year growth resulted from improved same facility revenues, higher acuity, favorable payer mix and prudent expense management efforts. Adjusted EBITDA margin of 21.3% improved 280 basis points (bps) year over year.
Total operating costs increased 2.3% year over year to $4.5 billion in the second quarter due to a higher supplies expense.
Segmental Details
Hospital Operations and Services: The segment recorded net operating revenues of $4 billion, which inched up 0.9% year over year on the back of improved same hospital admissions, higher acuity and favorable payer mix. The metric beat the Zacks Consensus Estimate of $3.92 billion and our estimate of $3.89 billion. Nevertheless, on a same-hospital basis, net patient service revenues grew 5.6% year over year.
Adjusted EBITDA climbed 25.1% year over year to $623 million in the second quarter resulting from higher same facility revenues, favorable payer mix and prudent expense management efforts. The metric outpaced the consensus mark of $505 million and our estimate of $480.6 million. Adjusted EBITDA margin of 15.6% improved 300 bps year over year.
Ambulatory Care: The segment’s net operating revenues rose 11.3% year over year to $1.3 billion in the quarter under review on the back of improved net revenue per case growth, facility buyouts and expansion of service lines. The metric outpaced the Zacks Consensus Estimate of $1.23 billion and our estimate of $1.24 billion.
Adjusted EBITDA was $498 million, which advanced 11.4% year over year, attributable to facility buyouts and solid net revenue per case growth. The metric beat the consensus mark of $496 million but fell short of our estimate of $516.3 million. Adjusted EBITDA margin remained flat year over year at 39.2%.
THC’s Financial Position (as of June 30, 2025)
Tenet exited the second quarter with cash and cash equivalents of $2.6 billion, which declined 13.1% from the 2024-end level.
Total assets of $28.7 billion dipped 0.8% from the figure at 2024-end.
Long-term debt, net of the current portion, amounted to $13.1 billion, which inched up marginally from the figure as of Dec. 31, 2024. The current portion of long-term debt totaled $84 million.
Total shareholders’ equity of $3.7 billion decreased 10.1% from the 2024-end level.
THC generated $1.8 billion of net cash from operations in the first half of 2025, which advanced 31.4% year over year. Free cash flows improved 23.4% year over year to $743 million.
THC’s Share Repurchase Update
THC bought back common shares worth $747 million in the second quarter of 2025. Management sanctioned an increase of $1.5 billion to the share repurchase program. As of July 22, 2025, the company had a leftover share repurchase authorization of $1.8 billion.
Tenet’s Outlook
THC expects third-quarter 2025 adjusted EBITDA to be 22.5-23.5% of its full-year 2025 adjusted EBITDA guided range.
Net operating revenues are currently within $20.95-$21.25 billion, higher than the earlier view of $20.6-$21 billion. The midpoint of the revised guidance indicates 2.1% growth from the 2024 figure.
Net operating revenues of the Hospital segment are forecasted to lie between $15.95 billion and $16.1 billion, higher than the prior guidance of $15.75-$16 billion. The midpoint of the updated outlook indicates a 0.7% decline from the 2024 figure. The metric at the Ambulatory Care unit is estimated within $5-$5.15 billion, up from the previous view of $4.85-$5 billion. The midpoint of the revised guidance implies 11.9% growth from the 2024 figure.
Adjusted EBITDA is likely to remain between $4.4 billion and $4.54 billion for 2025, higher from the prior view of $3.975-$4.175 billion. The midpoint of the updated guidance indicates 11.9% growth from the 2024 figure. Adjusted EBITDA margin is estimated to be in the 21-21.4% band compared with the earlier view of 19.3-19.9%.
Adjusted net income is projected between $1.415 billion and $1.475 billion, up from the prior outlook of $1.115-$1.220 billion. Adjusted EPS is presently anticipated within $15.55-$16.21, up from the earlier view of $11.99-$13.12. The mid-point of the revised outlook implies a 33.7% rise from the 2024 figure. Interest expense is currently estimated between $815 million and $825 million.
Net cash provided by operating activities is expected between $2.75 billion and $3.1 billion. Free cash flow is estimated to remain between $2.025 billion and $2.275 billion. Capital expenditures are projected in the range of $725-$825 million.
THC’s Zacks Rank
Tenet currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported second-quarter 2025 results so far, the bottom-line result of Abbott Laboratories ABT beat the Zacks Consensus Estimate.
Abbott Laboratories reported second-quarter 2025 adjusted EPS of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter’s level. Worldwide sales of $11.14 billion were up 7.4% year over year on a reported basis. The top line surpassed the Zacks Consensus Estimate by 0.6%. Organically, sales improved 6.9% year over year. Organic sales, ex-COVID, rose 7.5% year over year. Segment wise, Established Pharmaceuticals’ product sales increased 6.9% on a reported basis (7.7% on an organic basis) to $1.38 billion.
In the second quarter, the Medical Devices segment’s sales rose 13.4% year over year on a reported basis (12.2% organically) to $5.37 billion. The Diabetes Care division reported organic sales growth of 19.6% year over year, led by sales of continuous glucose monitors, which accounted for $1.90 billion of total sales. Structural Heart sales rose 11.7% and Heart Failure sales improved 14% year over year organically. In the second quarter, the gross profit rose 8.9% year over year to $6.29 billion. The gross margin expanded 79 basis points (bps) to 56.4%.
Upcoming Releases
Here are two other companies from the Medical space that are likely to report their respective quarterly earnings soon.
Genmab A/S GMAB has an Earnings ESP of +10.03% and a Zacks Rank of 1 at present.
The Zacks Consensus Estimate for GMAB’s second-quarter 2025 earnings is 39 cents per share, which indicates a 77.3% surge from the prior-year quarter.
Genmab’s earnings beat estimates in two of the trailing four quarters and missed the mark twice, the average surprise being 14.90%.
Harmony Biosciences Holdings, Inc. HRMY has an Earnings ESP of +16.35% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for HRMY’s second-quarter 2025 earnings is 80 cents per share, which indicates a four-fold increase from the year-ago quarter’s reported figure.
Harmony Biosciences’ earnings beat estimates in each of the trailing four quarters, the average surprise being 167.63%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

(RTTNews) - Genmab A/S (GMAB) announced that it will vigorously defend itself against allegations of trade secret misappropriation brought by AbbVie Inc. (ABBV).
AbbVie has filed a complaint in the U.S. District Court for the Western District of Washington based in Seattle. The complaint names Genmab A/S, ProfoundBio US Co., ProfoundBio (Suzhou) Co., Ltd., and former employees of AbbVie as defendants. The allegations center on claims that the defendants misappropriated AbbVie's trade secrets involving the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs). These claims are related to rinatabart sesutecan (Rina-S) and other ADC pipeline products developed by ProfoundBio, which was acquired by Genmab in May 2024.
AbbVie is seeking damages and broad injunctive reliefs. AbbVie's alleged trade secrets are related to the use of disaccharides to improve the hydrophilicity of drug-linkers in ADCs. AbbVie is not asserting or enforcing any patent rights against the defendants, and to Genmab's knowledge, AbbVie has not pursued any development of products incorporating their alleged trade secrets.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Genmab To Vigorously Defend Against AbbVie's Trade Secret Misappropriation Claims

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide license.
Shares of Genmab are falling 7.29 percent at 22.39 on Nasdaq.
The biotechnology company notd that the initial HexaBody-CD38 clinical data was promising and showed robust clinical efficacy. Following a thorough evaluation, and rigorous portfolio prioritization, Genmab will not be pursuing further clinical development of HexaBody-CD38.
Genmab said that it is "disappointed that J&J has decided not to advance HexaBody-CD38."
As per the development and option agreement Genmab has provided Johnson and Johnson with data from a clinical proof-of-concept study in multiple myeloma, including a head-to-head comparison with Darzalex faspro.
According Genmab, preliminary data submitted to J&J has demonstrated an overall response rate of 55 percent in the HexaBoby-CD38 IV arm vs. 52 percent in the daratumumab SC arm.
Further, Genmab said, due to the relatively short follow-up time, secondary efficacy endpoints including duration of response, progression-free survival, and overall survival were not mature yet. The study showed treatment emergent Adverse events above 20% in the Hexabody-CD38 arm. Adverse events leading to death included one patient in the HexaBody-CD38 IV arm and two patients in the daratumumab SC arm.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Genmab Reveals J&J's Decision Not To Advance Hexabody-CD38, Shares Fall

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.53 per unit.
With FBT trading at a recent price near $173.55 per unit, that means that analysts see 23.62% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are Genmab A/S (Symbol: GMAB), Catalyst Pharmaceuticals Inc (Symbol: CPRX), and BeiGene Ltd (Symbol: ONC). Although GMAB has traded at a recent price of $20.23/share, the average analyst target is 81.35% higher at $36.69/share. Similarly, CPRX has 39.31% upside from the recent share price of $23.06 if the average analyst target price of $32.12/share is reached, and analysts on average are expecting ONC to reach a target price of $266.90/share, which is 32.31% above the recent price of $201.72. Below is a twelve month price history chart comparing the stock performance of GMAB, CPRX, and ONC:
Combined, GMAB, CPRX, and ONC represent 9.17% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
First Trust NYSE Arca Biotechnology Index Fund ETF
FBT
$173.55
$214.53
23.62%
Genmab A/S
GMAB
$20.23
$36.69
81.35%
Catalyst Pharmaceuticals Inc
CPRX
$23.06
$32.12
39.31%
BeiGene Ltd
ONC
$201.72
$266.90
32.31%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
Top Ten Hedge Funds Holding KLTR
TYRA shares outstanding history
SEEL shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Add Up The Parts: FBT Could Be Worth $215

(RTTNews) - Genmab A/S (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).
The results demonstrated an overall response rate (ORR) of 96 percent and a complete response (CR) rate of 87 percent among 111 patients after a median follow-up of two years. Additionally, the study showed an estimated 21-month progression-free survival (PFS) rate of 80 percent and a two-year overall survival (OS) rate of 90 percent.
Additional data from the study showed an estimated 89 percent of complete responders to the combination therapy remained in CR at 18 months.
With the majority of patients being enrolled and treated during the global COVID-19 pandemic, COVID-19 was reported in 57 percent of patients and led to epcoritamab discontinuation in 13 percent of patients. Five cases of COVID-19 led to fatal treatment-emergent adverse events. The other most common treatment-emergent adverse events were neutropenia (62 percent) and cytokine release syndrome (CRS; 51 percent).
Cytokine release syndrome events with the 2-step step-up dose regimen were mostly low grade (38 percent Grade 1, 12 percent Grade 2, 2 percent Grade 3) and primarily occurred following the first full dose. All cytokine release syndrome cases resolved. One case of immune effector cell-associated neurotoxicity syndrome (ICANS) was reported (Grade 1). The cytokine release syndrome and ICANS cases did not lead to treatment discontinuation.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Genmab : Epcoritamab Combo Shows High Response Rates In 1b/2 Trial For R/R Follicular Lymphoma

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s pipeline with the August 2024 acquisition of Cerevel Therapeutics, a neuroscience drugmaker, for around $8.7 billion.
ABBV’s Positive Parkinson’s Study Data
In the TEMPO-1 study, patients who received two fixed doses (5mg and 15mg) of once-daily tavapadon, a D1/D5 dopamine receptor partial agonist, for 26 weeks achieved statistically significant improvement in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score. MDS-UPDRS is a scale used to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. The study also met a key secondary endpoint by demonstrating statistically significant improvement in experiences of daily living as measured by MDS-UPDRS Part II at week 26.
Another phase III study (adjunctive) on tavapadon, called TEMPO-3, met its primary endpoint. Top-line data from another phase III study, TEMPO-2, which is evaluating flexible doses of tavapadon, is expected by the end of the year.
The positive Parkinson’s study data comes as a breather for AbbVie after its other Parkinson’s candidate, ABBV-951, hit a roadblock, having faced FDA’s rejection twice. However, results from the remaining two studies will help determine tavapadon’s commercial opportunity.
Like tavapadon, AbbVie has several promising R&D programs in its pipeline with the potential to drive long-term growth. These include next-generation approaches in immunology, a focus on bispecifics, antibody-drug conjugates or ADCs as well as innovative therapies for neuropsychiatric and neurodegenerative disorders. Other than a strong pipeline, AbbVie also boasts some successful new medicines. However, it faces headwinds like biosimilar erosion of blockbuster immunology drug Humira, declining sales of Imbruvica and slowing sales of some aesthetic products.
Let us discuss these factors in detail to better analyze how to play the stock.
ABBV’s Successful New Drugs Skyrizi and Rinvoq
AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Sales of Humira are declining due to loss of exclusivity and biosimilar erosion. However, AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications. Both these medicines are likely to support top-line growth in the next few years. AbbVie expects the combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion by 2027. These drugs have the potential to replace Humira.
In the popular inflammatory bowel disease (IBD) space, which includes two conditions, ulcerative colitis (“UC”) and Crohn’s disease (”CD”), Rinvoq's uptake continues to be very strong in both indications. Skyrizi is seeing tremendous performance in CD and expects rapid access for the UC indication, for which approval was received in the United States in June and in the EU in July. AbbVie expects Skyrizi and Rinvoq to double their respective sales in IBD indications in 2024.
Meanwhile, new migraine drugs, Ubrelvy and Qulipta/Aquipta, represent a combined $3 billion-plus peak sales opportunity.
Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025 with a high single-digit CAGR through the end of the decade.
ABBV Boasts an Attractive Pipeline
AbbVie has several early/mid-stage pipeline candidates that have blockbuster potential. The company expects several regulatory submissions and approvals and key data readouts in the next 12 months.
For blood cancers and solid tumors, AbbVie has an exciting and diverse pipeline of promising new therapies like ABBV-383, a BCMA CD3 bispecific, in late-stage development for relapsed/refractory multiple myeloma and Teliso-V, a promising c-Met ADC, which has been developed for nonsquamous non-small cell lung cancer. AbbVie filed a biologics license application to the FDA for Teliso-V last week.
AbbVie and partner Genmab’s GMAB Epkinly/Tepkinly (formerly epcoritamab) was approved for relapsed or refractory (r/r) third-line diffuse large B-cell lymphoma in the United States and EU in 2023 and for third-line r/r follicular lymphoma in the United States in June 2024 and in EU in August.
AbbVie on an Acquisition Spree This Year
AbbVie has been on an acquisition spree lately, which is strengthening its pipeline. It has signed several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas.
In 2024, it acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating IBD. It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD. Among the larger deals, AbbVie acquired ImmunoGen, which added antibody-drug conjugate Elahere, and Cerevel Therapeutics in 2024.
ABBV Stock Price Increase & Attractive Valuation
AbbVie stock has gained 27.5% so far this year compared withan increase of 20.2% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.
ABBV Stock Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
The stock has also been consistently trading above its 50-day and 200-day moving averages since early July.
From a valuation standpoint, AbbVie appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 16.70 forward earnings, lower than 19.04 for the industry. The stock is cheaper than some other large drugmakers like Eli Lilly LLY and Novo Nordisk NVO.
ABBV Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings has risen from $10.86 to $10.87 per share over the past 60 days.For 2025, earnings estimates have risen from $12.12 to $12.14 per share over the past 60 days.
ABBV Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in ABBV Stock
AbbVie faces its share of headwinds like Humira biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and slow market growth trends for fillers in the United States and China. However, AbbVie has faced its biggest challenge — Humira’s patent cliff — quite well and looks set to return to robust growth next year. Strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta, should keep driving the company’s top line.
AbbVie expects its ex-Humira growth drugs, which cover more than 80% of its total sales, to outperform its initial expectations, driven by strong performance in immunology and oncology. It expects its ex-Humira growth platform to deliver nearly $6 billion of sales growth in 2024. Importantly, the erosion in Humira sales in the United States has been lower than management’s expectations. The stock has an attractive dividend yield of around 3.2%.
AbbVie’s reasonable valuation, rising estimates, a solid pipeline and the prospect of growth in sales and profits in 2025 are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Buying ABBV stock at the current attractive valuation can prove prudent for long-term investors.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Genmab A/S Sponsored ADR (GMAB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

(RTTNews) - AbbVie (ABBV) announced that the European Commission has granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy.
According to the company, Tepkinly is the first and only subcutaneous T-cell engaging bispecific antibody approved to treat both relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the European Union (EU), as well as the European Economic Area (EEA) countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
Epcoritamab, approved under the brand name Epkinly in the United States and Tepkinly in the European Union, has received regulatory approval for certain lymphoma indications in several countries.
Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the R/R FL indication and the R/R DLBCL indication.
AbbVie will continue to pursue regulatory submissions for epcoritamab across international markets. Both Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy and in combination across lines of therapy in a range of hematologic malignancies.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.